A Phase II Study of Maintenance Treatment With Sequential Bortezomib, Thalidomide and Dexamethasone Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Multiple Myeloma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bortezomib; Dexamethasone; Filgrastim; Melphalan; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Aug 2021 Biomarkers information updated
- 25 Jun 2013 Planned end date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 09 Aug 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.